Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission
Summary The Asia-Pacific region is home to more than half of the global population and
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …
[PDF][PDF] Epidemiology of liver diseases in India
D Mondal, K Das, A Chowdhury - Clinical Liver Disease, 2022 - Wiley Online Library
Epidemiology of Liver Diseases in India Page 1 114 |CliniCal liver Disease, vOl 19, nO 3,
MarCH 2022 An Official Learning Resource of AASLD review epidemiology of liver Diseases in …
MarCH 2022 An Official Learning Resource of AASLD review epidemiology of liver Diseases in …
[图书][B] Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and HCV diagnostics
World Health Organization - 2022 - books.google.com
Page 1 World Health Organization UPDATED RECOMMENDATIONS ON TREATMENT OF
ADOLESCENTS AND CHILDREN WITH CHRONIC HCV INFECTION, AND HCV SIMPLIFIED …
ADOLESCENTS AND CHILDREN WITH CHRONIC HCV INFECTION, AND HCV SIMPLIFIED …
[图书][B] Best practices in child and adolescent tuberculosis care
World Health Organization - 2018 - apps.who.int
The global tuberculosis (TB) and child health community has increasingly prioritized the
childhood TB epidemic. In 2013, the childhood TB subgroup developed and published the …
childhood TB epidemic. In 2013, the childhood TB subgroup developed and published the …
Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes
SM Borgia, C Hedskog, B Parhy… - The Journal of …, 2018 - academic.oup.com
Abstract Background Hepatitis C virus (HCV) exhibits great genetic diversity and is classified
into 7 genotypes (GTs), with varied geographic prevalence. Until the recent development of …
into 7 genotypes (GTs), with varied geographic prevalence. Until the recent development of …
[HTML][HTML] Etiology and mode of presentation of chronic liver diseases in India: A multi centric study
PS Mukherjee, S Vishnubhatla, DN Amarapurkar… - PloS one, 2017 - journals.plos.org
There is a paucity of health policy relevant data for chronic liver disease from India,
impeding formulation of an interventional strategy to address the issue. A prospective …
impeding formulation of an interventional strategy to address the issue. A prospective …
Hepatitis C: Is eradication possible?
A Lombardi, MU Mondelli… - Liver …, 2019 - Wiley Online Library
Hepatitis C has a relevant global impact in terms of morbidity, mortality and economic costs,
with more than 70 million people infected worldwide. In the resolution,“Transforming our …
with more than 70 million people infected worldwide. In the resolution,“Transforming our …
Burden of hepatitis C virus infection in India: a systematic review and meta‐analysis
A Goel, N Seguy, R Aggarwal - Journal of gastroenterology and …, 2019 - Wiley Online Library
Abstract Background and Aim Burden of hepatitis C in India is not known. We therefore
conducted a systematic review of the available data on anti‐hepatitis C virus (HCV) …
conducted a systematic review of the available data on anti‐hepatitis C virus (HCV) …
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting
Background & Aims The prevalence of anti-hepatitis C virus antibody in Punjab, India is
3.6%, with 728,000 people estimated to have viremic chronic hepatitis C (CHC). The Mukh …
3.6%, with 728,000 people estimated to have viremic chronic hepatitis C (CHC). The Mukh …
[HTML][HTML] Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of …
Background We undertook this study to assess the incremental cost per quality adjusted life
year (QALY) gained with the use of pan-genotypic sofosbuvir (SOF)+ velpatasvir (VEL) for …
year (QALY) gained with the use of pan-genotypic sofosbuvir (SOF)+ velpatasvir (VEL) for …